Literature DB >> 20576822

Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease.

Mehmet Kanbay1, Mardare Nicoleta, Yusuf Selcoki, Mustafa Ikizek, Murat Aydin, Beyhan Eryonucu, Murat Duranay, Ali Akcay, Ferah Armutcu, Adrian Covic.   

Abstract

BACKGROUND AND OBJECTIVES: Cardiovascular disease in chronic kidney disease (CKD) is explained in part by traditional cardiovascular risk factors; by uremia-specific factors; and by abnormalities of mineral metabolism, factors involved in its regulation, and in the vascular calcification process. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In an unselected population of 177 patients with calculated GFR (eGFR) between 90 and 30 ml/min per 1.73 m(2), the link between the mineral metabolism abnormalities (calcium, phosphorus, calcium-phosphorus product), regulatory factors (parathyroid hormone [PTH], intact PTH [iPTH], vitamin D, fibroblast growth factor 23 [FGF 23], and fetuin A), and the severity of coronary artery disease (CAD) assessed by coronary angiography were evaluated in three subgroups defined by tertiles of Gensini lesion severity score.
RESULTS: The mean serum values for FGF 23 in the entire study population was 28.1 ± 17.3 RU/ml and for fetuin A was 473.1 ± 156.2 μg/ml. Patients with eGFR < 60 ml/min per 1.73 m(2) had significantly higher values of FGF 23 compared with patients with eGFR > 60 ml/min per 1.73 m(2). The Gensini score values significantly correlated with gender; arterial hypertension; and HDL cholesterol, eGFR, iPTH, FGF 23, and fetuin A levels. After the adjustments for traditional and uremia-related cardiovascular risk factors, the FGF 23 and fetuin A remained significant predictors of the Gensini score.
CONCLUSIONS: This study suggests that in a relatively young population with mild-to-moderate alteration of kidney function and with less traditional cardiovascular risk factors, anomalies of the serum FGF 23 and fetuin A levels appear early in the course of disease and are independent major predictors for extent of CAD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20576822      PMCID: PMC2974377          DOI: 10.2215/CJN.02560310

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  27 in total

1.  Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guideline.

Authors:  Marlies Noordzij; Johanna C Korevaar; Friedo W Dekker; Elisabeth W Boeschoten; Willem J Bos; Raymond T Krediet; Patrick M Bossuyt; Ronald B Geskus
Journal:  Blood Purif       Date:  2008-02-28       Impact factor: 2.614

2.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry A J Struijker Boudier; Alberto Zanchetti; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Gerasimos Filippatos; Christian Funck-Brentano; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; José Luis Zamorano; Serap Erdine; Wolfgang Kiowski; Enrico Agabiti-Rosei; Ettore Ambrosioni; Lars H Lindholm; Margus Viigimaa; Stamatis Adamopoulos; Enrico Agabiti-Rosei; Ettore Ambrosioni; Vicente Bertomeu; Denis Clement; Serap Erdine; Csaba Farsang; Dan Gaita; Gregory Lip; Jean-Michel Mallion; Athanasios J Manolis; Peter M Nilsson; Eoin O'Brien; Piotr Ponikowski; Josep Redon; Frank Ruschitzka; Juan Tamargo; Pieter van Zwieten; Bernard Waeber; Bryan Williams
Journal:  J Hypertens       Date:  2007-06       Impact factor: 4.844

Review 3.  Fetuin-A and extraosseous calcification in uremia.

Authors:  Markus Ketteler
Journal:  Curr Opin Nephrol Hypertens       Date:  2005-07       Impact factor: 2.894

4.  Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.

Authors:  Orlando Gutierrez; Tamara Isakova; Eugene Rhee; Anand Shah; Julie Holmes; Gina Collerone; Harald Jüppner; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2005-05-25       Impact factor: 10.121

Review 5.  Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review.

Authors:  Mehmet Kanbay; David Goldsmith; Ali Akcay; Adrian Covic
Journal:  Blood Purif       Date:  2009-01-29       Impact factor: 2.614

6.  Chronic kidney disease as a predictor of cardiovascular disease (from the Framingham Heart Study).

Authors:  Nisha I Parikh; Shih-Jen Hwang; Martin G Larson; Daniel Levy; Caroline S Fox
Journal:  Am J Cardiol       Date:  2008-05-09       Impact factor: 2.778

7.  Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.

Authors:  Orlando M Gutiérrez; Michael Mannstadt; Tamara Isakova; Jose Alejandro Rauh-Hain; Hector Tamez; Anand Shah; Kelsey Smith; Hang Lee; Ravi Thadhani; Harald Jüppner; Myles Wolf
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

8.  Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.

Authors:  Danilo Fliser; Barbara Kollerits; Ulrich Neyer; Donna P Ankerst; Karl Lhotta; Arno Lingenhel; Eberhard Ritz; Florian Kronenberg; Erich Kuen; Paul König; Günter Kraatz; Johannes F E Mann; Gerhard A Müller; Hans Köhler; Peter Riegler
Journal:  J Am Soc Nephrol       Date:  2007-07-26       Impact factor: 10.121

9.  Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Authors:  Orlando M Gutiérrez; James L Januzzi; Tamara Isakova; Karen Laliberte; Kelsey Smith; Gina Collerone; Ammar Sarwar; Udo Hoffmann; Erin Coglianese; Robert Christenson; Thomas J Wang; Christopher deFilippi; Myles Wolf
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

Review 10.  [FGF23 in chronic kidney disease and kidney post-transplant patients].

Authors:  Al Negri
Journal:  Nefrologia       Date:  2009       Impact factor: 2.033

View more
  24 in total

Review 1.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2014-04-01       Impact factor: 28.314

Review 2.  Mineral metabolism and vitamin D in chronic kidney disease--more questions than answers.

Authors:  David J A Goldsmith; John Cunningham
Journal:  Nat Rev Nephrol       Date:  2011-05-03       Impact factor: 28.314

3.  Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III.

Authors:  Maureen A Murtaugh; Rebecca Filipowicz; Bradley C Baird; Guo Wei; Tom Greene; Srinivasan Beddhu
Journal:  Nephrol Dial Transplant       Date:  2011-08-02       Impact factor: 5.992

Review 4.  Mineral and bone disorders in children with chronic kidney disease.

Authors:  Claus Peter Schmitt; Otto Mehls
Journal:  Nat Rev Nephrol       Date:  2011-09-27       Impact factor: 28.314

5.  FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy.

Authors:  Sigrid Lundberg; Abdul Rashid Qureshi; Sara Olivecrona; Iva Gunnarsson; Stefan H Jacobson; Tobias E Larsson
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-01       Impact factor: 8.237

6.  Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate.

Authors:  Emilio González-Parra; Álvaro Aceña; Óscar Lorenzo; Nieves Tarín; María Luisa González-Casaus; Carmen Cristóbal; Ana Huelmos; Ignacio Mahíllo-Fernández; Ana María Pello; Rocío Carda; Ignacio Hernández-González; Joaquín Alonso; Fernando Rodríguez-Artalejo; Lorenzo López-Bescós; Alberto Ortiz; Jesús Egido; José Tuñón
Journal:  J Bone Miner Metab       Date:  2015-08-23       Impact factor: 2.626

7.  Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study.

Authors:  Orlando M Gutiérrez; Myles Wolf; Eric N Taylor
Journal:  Clin J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 8.237

Review 8.  The role of uric acid in mineral bone disorders in chronic kidney disease.

Authors:  Baris Afsar; Alan A Sag; Cinar Oztosun; Masanari Kuwabara; Mario Cozzolino; Adrian Covic; Mehmet Kanbay
Journal:  J Nephrol       Date:  2019-04-27       Impact factor: 3.902

Review 9.  Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease.

Authors:  Armando Luis Negri
Journal:  Int Urol Nephrol       Date:  2013-01-08       Impact factor: 2.370

Review 10.  Fibroblast growth factor 23, Klotho, and disordered mineral metabolism in chronic kidney disease: unraveling the intricate tapestry of events and implications for therapy.

Authors:  Orlando M Gutiérrez
Journal:  J Ren Nutr       Date:  2013-05       Impact factor: 3.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.